Search

JPMorgan analyst Richard Vosser placed a 'Negative Catalyst Watch' on shares of Neutral-rated Novartis (NVS) ahead of the NATALEE data presentation on June 2. The firm's analysis of the potential [...]

Eli Lilly announced that data from its oncology portfolio will be presented at the 2022 ASCO Annual Meeting. The data include new analyses from studies of Verzenio - abemaciclib, a [...]

Quest Diagnostics (DGX) will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx - Dako Omnis - immunohistochemistry companion diagnostic. On October 13, the FDA approved Eli Lilly's (LLY) [...]

Eli Lilly and Company announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio in combination with standard adjuvant endocrine therapy for the treatment [...]

The FDA has approved Eli Lilly and company's Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, [...]

Agilent (A) 'announced its Ki-67 IHC MIB-1 pharmDx is now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence, for whom [...]

Eli Lilly announced new data for the investigational use of Verzenio in high risk early breast cancer, and for its oral selective estrogen receptor degrader LY3484356 at the 57th Annual [...]

Eli Lilly announced patient-reported outcomes, or PRO, for the investigational use of Verzenio in combination with standard adjuvant endocrine therapy, or ET, for the treatment of hormone receptor-positive, or HR+, [...]

After Eli Lilly (LLY) presented detailed data on its monarchE study at ESMO and in a published journal, Morgan Stanley analyst David Risinger noted that Verzenio demonstrated a 'compelling' 25% [...]

Data from 20 studies across Eli Lilly's oncology product portfolio will be presented at the European Society for Medical Oncology, or ESMO, virtual congress, September 19-21. The data include results [...]

JPMorgan analyst Chris Schott raised the firm's price target on Eli Lilly to $190 from $175 and keeps an Overweight rating on the shares after positive data for Verzenio in [...]

Eli Lilly announced Verzenio in combination with standard adjuvant endocrine therapy, or ET, has met the primary endpoint of invasive disease-free survival, or IDFS, significantly decreasing the risk of breast [...]

As previously reported, Guggenheim analyst Seamus Fernandez upgraded Eli Lilly to Buy from Neutral with an $182 price target following this morning's positive monarchE study results. Earlier, Eli Lilly announced [...]

Morgan Stanley analyst David Risinger said the failure of Pfizer's (PFE) early stage adjuvant, after-surgery, breast cancer trial with Ibrance, PALLAS, at an interim analysis may suggest incremental risk for [...]

Eli Lilly and Company announced that Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive, human epidermal growth factor receptor [...]

Eli Lilly announced Verzenio in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or [...]

Eli Lilly announced that Verzenio demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial. These results were from a pre-planned interim analysis. MONARCH [...]

Eli Lilly announced 'npj Breast Cancer' published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical benefit of Verzenio plus endocrine therapy in [...]

Pharmaceutical revenue in Q2 grew 10%. New pharmaceutical products, including Trulicity, Taltz, Cyramza, Basaglar, Jardiance, Lartruvo, Verzenio, and Olumiant, represented 28% of total revenue and drove 12% volume [...]

New pharmaceutical products, including Trulicity, Cyramza, Basaglar, Jardiance, Taltz, Lartruvo, Olumiant, and Verzenio, represented 25% of total revenue and drove 11% volume growth. Revenue in the U.S. increased 8%, to [...]

Eli Lilly announced that the U.S. FDA has approved Verzenio in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive, human [...]